Cantor Fitzgerald Issues Positive Estimate for DNTH Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Analysts at Cantor Fitzgerald lifted their FY2025 EPS estimates for Dianthus Therapeutics in a research report issued on Thursday, March 13th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings of ($3.16) per share for the year, up from their prior estimate of ($3.46). The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.61) per share.

DNTH has been the topic of a number of other reports. Raymond James raised shares of Dianthus Therapeutics to a "moderate buy" rating in a report on Thursday, December 12th. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Wedbush reaffirmed an "outperform" rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They issued a "buy" rating on the stock. Finally, Guggenheim reissued a "buy" rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $52.14.

Dianthus Therapeutics Price Performance

DNTH stock remained flat at $20.59 during midday trading on Monday. 73,419 shares of the company's stock traded hands, compared to its average volume of 237,227. Dianthus Therapeutics has a 12-month low of $18.13 and a 12-month high of $33.77. The firm has a market cap of $609.40 million, a PE ratio of -8.25 and a beta of 1.82. The business has a fifty day moving average price of $22.24 and a two-hundred day moving average price of $24.67.

Remove Ads

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.85) by $0.04. The firm had revenue of $1.33 million during the quarter, compared to analysts' expectations of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%.

Institutional Trading of Dianthus Therapeutics

Several large investors have recently bought and sold shares of DNTH. R Squared Ltd acquired a new stake in Dianthus Therapeutics in the fourth quarter valued at about $26,000. Quest Partners LLC raised its position in Dianthus Therapeutics by 112,400.0% in the third quarter. Quest Partners LLC now owns 1,125 shares of the company's stock valued at $31,000 after purchasing an additional 1,124 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in Dianthus Therapeutics in the fourth quarter valued at about $33,000. KBC Group NV bought a new position in shares of Dianthus Therapeutics during the fourth quarter worth about $35,000. Finally, BNP Paribas Financial Markets bought a new position in shares of Dianthus Therapeutics during the fourth quarter worth about $59,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.